Xiushi Bio Secures Nearly RMB 100 Million in Pre-A Funding to Accelerate Diversified Commercial Applications of Its Proprietary Peptide Biosynthesis Platform

Recently,Xiushi Biopharma Co., Ltd. (hereinafter referred to as “XIUSHI”) announced that it has completed a Pre-A financing round of nearly RMB 100 million, led by Chuangjing Capital, with participation from Huatai Zijin (Jiangsu) Equity Investment Fund, Jinyu Maowu Investment Management, and Xiaofanzhuo Ventures.

The proceeds from this round of financing will be primarily used to further invest in the construction of the company’s proprietary innovative peptide biosynthesis technology platform and the R&D of its diversified pipeline, to complete and expand the construction of compliant peptide drug production lines, and to accelerate the commercialization of the company’s advantageous technologies and products both domestically and internationally.

G&G Capital served as the exclusive financial advisor for this round of financing, with support from Linglu Capital.

Founded in 2020, XIUSHI boasts a core team with extensive experience in synthetic biology technology development and pharmaceutical engineering. Leveraging its innovative technology platform and scalable bio-manufacturing capabilities in the field of peptide biosynthesis, XIUSHI provides industry partners with novel and highly attractive biosynthetic solutions for peptide drugs.

Currently, XIUSHI has achieved industrial-scale production of various biosynthetic peptide products, offering capacity-building and cost advantages that surpass those of traditional biological and chemical synthesis methods, and has secured collaborative orders from numerous renowned pharmaceutical companies both domestically and internationally.

After more than three years of development, XIUSHI has achieved a series of breakthrough synthetic strategies and process methodologies in the field of peptide biosynthesis. In particular, it has made substantial industrialization progress in the large-scale biosynthesis of short peptides, complex cyclic peptides, and non-natural amino acid-modified peptides. This provides innovative peptide drugs with CMC options that offer greater economic efficiency and advantages in scale-up, earning widespread recognition from downstream pharmaceutical companies.

Moving forward, XIUSHI will continue to expand its peptide biosynthesis technology platform to provide more diverse and efficient solutions. Meanwhile, it will apply biosynthetic strategies and process methodologies to a broader range of peptide products beyond peptide therapeutics, thereby driving more diversified commercial applications in the discovery, development, and manufacturing of peptides.

Regarding this round of financing,Dr. Wu Yinsong, Founder and CEO of XIUSHIXIUSHI stated, “We are deeply honored to have earned the trust and support of the investors in this funding round. The completion of this financing marks a significant milestone in XIUSHI’s development. We will continue to accelerate the implementation of our core technology platform, expand our advantages in the engineering and scale-up of biosynthetic peptide manufacturing, achieve commercialization of a diversified portfolio of peptide products, and drive innovative and green development within the peptide industry.”

As the lead investor in this round of financing,Mr. Song Longtao, Managing Partner of Chuangjing Capital“The global pharmaceutical and medical aesthetics markets for peptides are expected to remain robust. Biosynthetic production offers low costs and significant competitive advantages. The XIUSHI team possesses extensive experience in industrial development within the fields of biomanufacturing and biopharmaceuticals, with strong and stable collaboration. They have established an industry-leading platform for peptide biosynthesis technology, earning high recognition from numerous downstream clients. We are confident in the technological advancement and business acumen of the XIUSHI team and look forward to their continued efforts in commercializing a diverse portfolio of biosynthetic peptide products, thereby leading the development of the peptide biosynthesis industry.”

Currently, relying on a single production process, such as chemical synthesis, can no longer meet the development demands of peptide products. The rapid advancement of biosynthetic technologies has introduced novel technical approaches to peptide synthesis. Moreover, the integrated application of different technologies allows for leveraging their respective strengths while mitigating weaknesses, thereby significantly enhancing peptide production efficiency. In the future, guided by emerging technologies, peptide synthesis will break through existing technical limitations, achieving high-efficiency manufacturing characterized by lower costs, larger scales, and environmental sustainability.

As an investor in this funding round,Huatai Zijin (Jiangsu) Equity Investment FundIt stated: “In recent years, Huatai Zijin (Jiangsu) Equity Investment Fund has made significant investments across the upstream and downstream sectors of the peptide drug industry. Leveraging their unique pharmacological properties and broad application prospects, peptides are playing an increasingly important role in drug development. Currently, chemical synthesis remains the predominant method for peptide production; however, biosynthesis, with its advantages of lower production costs, strong targeted expression, and large-scale manufacturing capability, represents the future trend. XIUSHI has innovatively established a biosynthesis platform for short peptides and complex cyclic peptides, demonstrating significant environmental and cost advantages in the synthesis of certain peptide varieties. With continued technological accumulation and breakthroughs, XIUSHI is poised to achieve further innovations in the biosynthesis of a wider range of peptides and is expected to emerge as a leading enterprise in the field of biosynthetic peptides.”

Peptides, with their advantages of high biological activity and high selectivity, have not only achieved significant success in the pharmaceutical field but also hold broad prospects in the consumer sector.

As an investment institution that has long focused on the application of peptide ingredients in the consumer healthcare sector,Li Hongsen, Partner at Jinyu Maowu Investment Management“The peptide components hold immense application prospects in the fields of pharmaceuticals, active ingredients for cosmetics, and functional foods. XIUSHI’s technology platform spans multiple domains, including peptide screening and design, biosynthesis, and chemical modification. Within a short period, it has already achieved mass production and application across several pipelines in the pharmaceutical and cosmetic ingredient sectors. The team’s technical capabilities and execution are truly admirable. Jinyu Maowu Investment Management has long focused on healthcare consumption, particularly research into related upstream raw materials, and has invested in well-known industry chain projects such as Botanee (300957), Xuan Kai, Vicky, and Huasai. In the future, we will collaborate with the industrial ecosystem to jointly empower and accelerate XIUSHI’s development.”

Regarding this round of financing,Zhang Xiaoyan, Partner at Xiao Fan Zhuo Venture CapitalXIUSHI stated: “Peptide drugs are a global R&D hotspot, and semaglutide is poised to compete for the title of the next-generation ‘blockbuster drug.’ The volume production of GLP-1 drug active pharmaceutical ingredients (APIs) is expected to surge, while peptide raw materials also hold significant market potential in the medical aesthetics sector. Leveraging its platform technology, XIUSHI can carry out the biosynthesis of various complex peptides, demonstrating distinct advantages in product quality, engineering processes, environmental sustainability, and production costs. With a team that combines scientific research expertise with extensive industrialization experience, we believe XIUSHI will play a pivotal role in driving the rapid development of the peptide industry.”

Chuangjing Capital specializes in investment management within the healthcare and medical industry. By leveraging high-quality industrial resources and integrating extensive investment expertise, we identify outstanding entrepreneurs in the sector and provide multi-dimensional professional support. This approach creates a complete closed-loop ecosystem encompassing “project sourcing, investment, industrial empowerment, and exit,” thereby fostering the development of the healthcare and medical industry. Our management team hails from leading investment institutions and industry pioneers, including Hillhouse Capital, Johnson & Johnson Medical, and China National Pharmaceutical Group (Sinopharm). To date, we have jointly established multiple funds in partnership with listed company Hotgen Biotech (688068) and BoRui Technology, a leader in the molecular diagnostics industry.